Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445399 versus placebo in adults with non-cystic fibrosis bronchiectasis
2025-523403-29-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Jun 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing SAR445399 with Matched placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in mucus plug score derived from chest high-resolution computed tomography. Planned start Jun 2026; status: authorised.
02
Drugs
SAR445399
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on 2025-523403-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523403-29-00.